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EGFR is frequently overexpressed on several cancers,
and two targeted antibodies are FDA approved but differ
by isotype. Cetuximab (IgG1 isotype) has been shown to
be effective at both inhibiting downstream signaling of
EGFR and activating anti-tumor, cellular immune
mechanisms. While panitumumab (IgG2 isotype) can
inhibit downstream EGFR signaling similar to cetuxi-
mab, panitumumab might also induce antibody-depen-
dent cell cytotoxicity (ADCC) or adaptive immunity. We
sought to investigate the cellular immunity specifically
activated by cetuximab or panitumumab showing that
both mAb primarily activate NK cells, although cetuxi-
mab was significantly more potent than panitumumab.
We also observed that although panitumumab may acti-
vate monocytes through the CD32 (FcgRIIa) receptor,
neither mAb activated monocytes sufficiently to mediate
ADCC. Cetuximab enhanced DC maturation to a greater
extent than panitumumab, corresponding with improved
cross presentation of tumor antigen by cetuximab com-
pared with panitumumab. Indeed, improved adaptive
immune responses with increased EGFR-specific cytotoxic
CD8+ T cells were present in patients treated with cetuxi-
mab compared to those treated with panitumumab. These
results suggest that although panitumumab effectively
inhibits EGFR signaling to a similar extent as cetuximab, it
is less effective at mediating anti-tumor, cellular immune
mechanisms which may be crucial for effective therapy for
HNSCC.
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